Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Cara E. Shields"'
Autor:
Cara E. Shields, Sindhu Potlapalli, Selma M. Cuya‐Smith, Sarah K. Chappell, Dongdong Chen, Daniel Martinez, Jennifer Pogoriler, Komal S. Rathi, Shiv A. Patel, Kristianne M. Oristian, Corinne M. Linardic, John M. Maris, Karmella A. Haynes, Robert W. Schnepp
Publikováno v:
Molecular Oncology, Vol 15, Iss 8, Pp 2156-2171 (2021)
Rhabdomyosarcoma (RMS) is an aggressive pediatric soft tissue sarcoma. There are two main subtypes of RMS, alveolar rhabdomyosarcoma (ARMS) and embryonal rhabdomyosarcoma. ARMS typically encompasses fusion‐positive rhabdomyosarcoma, which expresses
Externí odkaz:
https://doaj.org/article/54ae8d279f04470ca6884d0bbba468ac
Publikováno v:
Regenerative Engineering and Translational Medicine. 8:446-455
Publikováno v:
bioRxiv
Scientists have used small molecule inhibitors and genetic knockdown of gene-silencing polycomb repressive complexes (PRC1/2) to determine if restoring the expression of tumor suppressor genes can block proliferation and invasion of cancer cells. A m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60891b57bbc88aea12f2fd8b519297ff
https://europepmc.org/articles/PMC9900809/
https://europepmc.org/articles/PMC9900809/
Autor:
Sindhu Potlapalli, Robert W. Schnepp, Dongdong Chen, Corinne M. Linardic, Jennifer Pogoriler, Karmella A. Haynes, Selma M. Cuya-Smith, John M. Maris, Cara E. Shields, Shiv A. Patel, Daniel Martinez, Komal S. Rathi, Sarah K. Chappell, Kristianne M. Oristian
Publikováno v:
Molecular Oncology, Vol 15, Iss 8, Pp 2156-2171 (2021)
Molecular Oncology
Molecular Oncology
Rhabdomyosarcoma (RMS) is an aggressive pediatric soft tissue sarcoma. There are two main subtypes of RMS, alveolar rhabdomyosarcoma (ARMS) and embryonal rhabdomyosarcoma. ARMS typically encompasses fusion‐positive rhabdomyosarcoma, which expresses
Autor:
Alan Cabrera, Hailey I. Edelstein, Fokion Glykofrydis, Kasey S. Love, Sebastian Palacios, Josh Tycko, Meng Zhang, Sarah Lensch, Cara E. Shields, Mark Livingston, Ron Weiss, Huimin Zhao, Karmella A. Haynes, Leonardo Morsut, Yvonne Y. Chen, Ahmad S. Khalil, Wilson W. Wong, James J. Collins, Susan J. Rosser, Karen Polizzi, Michael B. Elowitz, Martin Fussenegger, Isaac B. Hilton, Joshua N. Leonard, Lacramioara Bintu, Kate E. Galloway, Tara L. Deans
Publikováno v:
Cabrera, A, Edelstein, H I, Glykofrydis, F, Love, K S, Palacios, S, Tycko, J, Zhang, M, Lensch, S, Shields, C E, Livingston, M, Weiss, R, Zhao, H, Haynes, K A, Morsut, L, Chen, Y Y, Khalil, A S, Wong, W W, Collins, J J, Rosser, S J, Polizzi, K, Elowitz, M B, Fussenegger, M, Hilton, I B, Leonard, J N, Bintu, L, Galloway, K E & Deans, T L 2022, ' The sound of silence : Transgene silencing in mammalian cell engineering ', Cell Systems, vol. 13, no. 12, pp. 950-973 . https://doi.org/10.1016/j.cels.2022.11.005
To elucidate principles operating in native biological systems and to develop novel biotechnologies, synthetic biology aims to build and integrate synthetic gene circuits within native transcriptional networks. The utility of synthetic gene circuits
Autor:
Melanie Weingart, Robert W. Schnepp, Komal S. Rathi, John M. Maris, Dongdong Chen, Julie Cox, Cara E. Shields, Kristopher R. Bosse, Priya Khurana, Adeiye Pilgrim, Jo Lynne Rokita, Oskar Laur, Jayabhargav Annam, Grace Essien, Daisy Li, Selma M. Cuya
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 22, Iss 6, Pp 231-241 (2020)
Neoplasia (New York, N.Y.)
Neoplasia (New York, N.Y.)
Neuroblastoma is an aggressive pediatric malignancy of the neural crest with suboptimal cure rates and a striking predilection for widespread metastases, underscoring the need to identify novel therapeutic vulnerabilities. We recently identified the
Abstract A47: BMI1 constitutes a novel therapeutic vulnerability in fusion-positive rhabdomyosarcoma
Autor:
Sindhu Potlapalli, Komal S. Rathi, Robert W. Schnepp, Cara E. Shields, Selma M. Cuya, Sarah K. Chappell, Shiv A. Patel
Publikováno v:
Cancer Research. 80:A47-A47
Background: Despite intense efforts within pediatric oncology, novel, effective therapy for alveolar rhabdomyosarcoma, known as fusion-positive rhabdomyosarcoma (FP RMS) given the PAX-FOXO1 fusions characteristic of the disease, remains unrealized. L
Autor:
Sarah K. Chappell, Shiv A. Patel, Sindhu Potlapalli, Cara E. Shields, Selma M. Cuya, Komal S. Rathi, Robert W. Schnepp
Publikováno v:
Cancer Research. 79:3838-3838
Background: Rhabdomyosarcoma (RMS) is an extremely aggressive soft tissue sarcoma which affects mainly children. There are two subtypes: alveolar rhabdomyosarcoma (ARMS) and embryonal rhabdomyosarcoma (ERMS). ARMS is characterized by PAX-FOXO1 fusion